What question did this study set out to answer?

To investigate the effects of pemafibrate on chronic kidney disease patients and explore factors contributing to frailty during hospitalization.

March 28, 2026Open Access

WCN26-6562 Rationale and protocol of the Japan Kidney Association–Pemafibrate Intervention for Chronic Kidney Disease Patients Study (JKAPI-CKD Study)

Key Points

To investigate the effects of pemafibrate on chronic kidney disease patients and explore factors contributing to frailty during hospitalization.
Studied hospitalized patients with chronic kidney disease (CKD)
Monitored changes in frailty status using clinical assessments
Evaluated associations with age, BMI, GNRI, ischemic heart disease, and HD therapy
Observed a 39.8% decline in frailty during hospitalization
Identified older age, higher BMI, and lower GNRI as risk factors for frailty progression
Suggested that timely cardiac rehabilitation may reduce worsening frailty in these patients.

Abstract

Conclusion:In this study of patients hospitalized for CVD and receiving acute-phase CR, an in-hospital decline in CFS was observed in 39.8% of cases.Older age, higher BMI, lower GNRI, ischemic heart disease and HD therapy were independently associated with this decline.These interrelated factors including chronic vulnerability, treatment-related stress, and nutritional imbalance may collectively accelerate frailty progression during hospitalization.Including those on HD, and timely implementation of cardiac rehabilitation may help mitigate further frailty progression and support functional recovery.I have no potential conflict of interest to disclose.I used generative AI and AI-assisted technologies in the writing process.During the preparation of this work, the authors used ChatGPT (OpenAI) solely to improve language and readability.After using this tool,

Mark Helpful

Bookmark

Relay

View Full Paper